{"prompt": "['APPENDIX 10: AUTHORIZED AND PROHIBITED CONCOMITTANT MEDICATIONS', 'Supportive medication/class of drug:', 'Usage:', 'Concomitant medications or treatments', 'To be administered as prescribed by the', '(e.g., acetaminophen or diphenhydramine)', 'Investigator', 'deemed necessary to provide adequate', 'prophylactic or supportive care, except for', 'those', 'medications', 'identified', 'as', '\"prohibited,\" as listed above', 'Best supportive care (including antibiotics,', 'Should be used, when necessary, for all', 'nutritional support, correction of metabolic', 'patients', 'disorders, optimal symptom control, and', 'pain management [including palliative', 'radiotherapy to non-target lesions, etc])', 'Inactivated viruses, such as those in the', 'Permitted', 'influenza vaccine', 'Prohibited medication/class of drug:', 'Usage:', 'Any investigational anticancer therapy', 'Should not be given concomitantly whilst', 'other than those under investigation in this', 'the patient is on study treatment', 'study', 'mAbs against CTLA-4, PD-1, or PD-L1', 'Should not be given concomitantly whilst', 'other than those under investigation in this', 'the patient is on study treatment', 'study', 'Any', 'concurrent', 'chemotherapy,', 'Should not be given concomitantly whilst', 'radiotherapy, immunotherapy, or biologic', 'the patient is on study treatment.', 'or hormonal therapy for cancer treatment', '(Concurrent use of hormones for non-', 'other than those under investigation in this', 'cancer-related conditions [e.g., insulin for', 'study', 'diabetes and hormone replacement therapy]', 'is acceptable. Local treatment of isolated', 'lesions, excluding target lesions, for', 'palliative intent is acceptable [e.g., by local', 'surgery or radiotherapy])', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 112 de 123']['Immunosuppressive medications including,', 'Should not be given concomitantly, or used', 'but not limited to, systemic corticosteroids', 'for premedication prior to the I-O infusions.', 'at doses exceeding 10 mg/day of', 'The following are allowed exceptions:', 'prednisone or equivalent, methotrexate,', 'Use', 'of', 'immunosuppressive', 'azathioprine, and tumor necrosis factor-a', 'medications for the management of', 'blockers', 'IP-related AEs.', 'short-term', 'premedication', 'for', 'patients receiving combination', 'agent', 'durvalumuab', 'tremelimumab', 'where', 'the', 'prescribing information for the', 'agent requires the use of steroids', 'for documented hypersensitivity', 'reactions.', 'Use in patients with contrast', 'allergies.', 'In addition, use of inhaled, topical,', 'and intranasal corticosteroids is', 'permitted.', 'A temporary period of steroids will be', 'allowed if clinically indicated and', 'considered to be essential for the', 'management of non-immunotherapy related', 'events experienced by the patient (e.g.,', 'chronic obstructive pulmonary disease,', 'radiation, nausea, etc).', 'Drugs with laxative properties and herbal or', 'Should be avoided through 90 days after the', 'natural remedies for constipation', 'last dose of tremelimumab during the study.', 'Sunitinib', 'Should not be given concomitantly or', 'through 90 days after the last dose of', 'tremelimumab (acute renal failure has been', 'reported with combination therapy of', 'tremelimumab and sunitinib).', 'EGFR TKIs', 'Should not be given concomitantly.', 'Should be used with caution in the 90 days', 'post last dose of durvalumab.', 'Increased incidences of pneumonitis (with', 'third generation EGFR TKIs) and increased', 'incidence of transaminase increases (with', '1st generation EGFR TKIs) has been', 'reported when durvalumab has been given', 'concomitantly.', 'Live attenuated vaccines', 'Should not be given through 30 days after', 'the last dose of IP (including SoC).', 'Herbal and natural remedies which may', 'Should not be given concomitantly unless', 'have immune-modulating effects', 'agreed by the sponsor.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 113 de 123']\n\n###\n\n", "completion": "END"}